ArticleMalaria journal2026
A six years trend analysis of malaria prevalence in Central Ethiopia Region.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging predominance of Plasmodium vivax and its contribution to severe malaria in Central Ethiopia: a mixed retrospective-prospective study from two tertiary hospitals.BMC infectious diseases · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria continues to be the foremost deadly disease and a cause of substantial economic deficit in Ethiopia. Data from malaria monitoring programs can be used to assess prevalence and trends of the disease over time in a way to inform policy makers and prioritize control strategies. The current study assessed the malaria case trend between 2019 and 2024 based on data from 12 districts and two towns of Hadia, Gurage and Yem zones in Central Ethiopia Region.
methodsA retrospective study design was employed to assess a six-year (2019-2024) trend of malaria cases in 12 districts and two towns selected purposively based on their location in the Ghibe valley and level of malaria burden with the support of local health authorities. District level aggregated malaria surveillance data was obtained from archives of the district and zonal health offices, carefully reviewed and analyzed. Descriptive statistics was used to calculate frequencies and percentages of seasonal and yearly malaria suspected as well as Plasmodium falciparum and Plasmodium vivax infected cases using Statistical Package for the Social Sciences version 25 software. Pearson Chi-square (χ2) was used for the test of statistical differences between/among variables. A post-hoc analysis of pairwise comparisons was carried out for identifying the specific significant difference among the groups.
resultsThere were 86,604 (23.5%) Plasmodium positive individuals among the total 368,490 suspected in the previous six years period. Among the 86,604 Plasmodium positive cases, 61% were attributed to P. falciparum and 39% to P. vivax. The analysis showed increasing trend of the Plasmodium infected cases starting from 2019 with some fluctuations. The number of cases peaked in May (13,811;15.9%), autumn season (27,266; 31.5%) and spring season (25,555; 29.5% of Ethiopia. The distribution of P. falciparum and P. vivax cases differed significantly across the districts, months, seasons and years.
conclusionPlasmodium falciparum and P. vivax are endemic in Hadia, Gurage and Yem zones of Central Ethiopia Region. The number of cases has been increasing since 2019 in the region and highest in May, June, October and September. Furthermore, the cases peaked during the autumn and spring Ethiopian seasons, which coincide with the key farming and harvesting seasons. There is a need to sustain and scale up existing malaria intervention measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.